Trial Profile
Single blind study to assess the efficacy and tolerance of BF 2.649 in adults suffering from Attention Deficit/Hyperactivity Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 May 2022
Price :
$35
*
At a glance
- Drugs Pitolisant (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Bioprojet
- 31 Mar 2022 Status changed from recruiting to completed.
- 31 May 2011 New trial record